克唑替尼治疗NSCLC的疗效观察及安全性评价

Efficacy and Safety Evaluation of Treatment of NSCLC with Crizotinib

目的探讨克唑替尼治疗NSCLC的临床疗效、生存质量、无进展生存时间及不良反应,明确该药的临床疗效,利于临床推广。方法选取2017年4月-2018年4月收治的中晚期NSCLC患者40例,随机分为实验组与对照组,每组20例。实验组给予克唑替尼治疗,对照组给予多西他赛单药化疗,比较两组的临床疗效与安全性。结果治疗1个月后,实验组的有效率及控制率明显高于对照组,差异有统计学意义(P <0. 05);不良反应比较,无统计学差异。两组病人均随访18个月,生存情况比较,差异有统计学意义(P <0. 05)。结论克唑替尼治疗ALK基因阳性的NSCLC患者,临床疗效显著,不良反应少,优于常规治疗。

Objective To investigate the clinical efficacy,quality of life,non progressive survival time and adverse reactions of Crizotinib in the treatment of NSCLC. Methods 40 cases of middle and late NSCLC patients who were treated in the department of respiration of the Affiliated Hospital of Shenyang Medical College from April 2017 to April 2018 were randomly divided into the experimental group and the control group,with 20 cases in each group. The experimental group was given the treatment of Crizotinib,while the control group was given docetaxel single chemotherapy. The clinical efficacy and safety of the two groups were compared. Results After 1 months of treatment,the efficiency and control rate of the experimental group were significantly higher than that of the control group. The difference was statistically significant（ P 〈0. 05）,and there was no statistical difference in the adverse reaction. The patients in the two groups were followed up for 18 months,and the difference was statistically significant（ P 〈0. 05）. Conclusions The treatment of ALK gene positive NSCLC patients with Crizotinib is effective and less adverse reaction than conventional treatment.